Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Adhoc Press Release
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Meeting minutes German version
Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration
Kuros Biosciences to present at upcoming U.S. spine conferences
Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations
Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals